Research programme: histone deacetylase inhibitors - KalypsysAlternative Names: KD-5170
Latest Information Update: 11 Mar 2009
At a glance
- Originator Kalypsys
- Class Small molecules
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 26 Aug 2004 Preclinical trials in Cancer in USA (PO)